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Abstract: In this retrospective pilot study, the expression of the prostate-specific 
membrane antigen (PSMA), the epithelial cell adhesion molecule (EpCAM), the vascular 
endothelial growth factor (VEGF) and the gastrin-releasing peptide receptor (GRPR) in 
locally recurrent prostate cancer after brachytherapy or external beam radiotherapy (EBRT) 
was investigated, and their adequacy for targeted imaging was analyzed. Prostate cancer 
specimens were collected of 17 patients who underwent salvage prostatectomy because of 
locally recurrent prostate cancer after brachytherapy or EBRT. Immunohistochemistry was 
performed. A pathologist scored the immunoreactivity in prostate cancer and stroma. 
Staining for PSMA was seen in 100% (17/17), EpCAM in 82.3% (14/17), VEGF in 82.3% 
(14/17) and GRPR in 100% (17/17) of prostate cancer specimens. Staining for PSMA, 
EpCAM and VEGF was seen in 0% (0/17) and for GRPR in 100% (17/17) of the 
specimens’ stromal compartments. In 11.8% (2/17) of cases, the GRPR staining intensity 
of prostate cancer was higher than stroma, while in 88.2% (15/17), the staining was equal. 
Based on the absence of stromal staining, PSMA, EpCAM and VEGF show high tumor 
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distinctiveness. Therefore, PSMA, EpCAM and VEGF can be used as targets for the 
bioimaging of recurrent prostate cancer after EBRT to exclude metastatic disease and/or to 
plan local salvage therapy. 
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1. Introduction 
Prostate cancer is the most commonly diagnosed cancer among men, and its incidence rates remain 
as the highest in many regions of the world [1]. About 18% of patients with localized disease develop 
a prostate-specific antigen (PSA) recurrence within five years after brachytherapy and external beam 
radiotherapy (EBRT) with doses higher than 72 Gy. This is in contrast to 49% of patients who were 
treated with doses less than 72 Gy [2]. At present, there is no imaging modality that can accurately 
discriminate between locally and distant recurrent prostate cancer after treatment with curative intent. 
Selecting patients for salvage cryotherapy of the prostate or salvage prostatectomy by excluding 
distant metastases proves a diagnostic challenge. 
New diagnostic techniques are needed to improve the imaging of recurrent prostate cancer. 
Furthermore, although early-stage and locally recurrent prostate cancer can be cured, treatment of 
metastasized disease is currently only palliative, making it important for new therapeutic applications 
to be devised [3].  
Significant expression of certain antigens in prostate cancer as compared to normal tissue could be 
used for antigen-targeted imaging or therapy. Numerous pre-clinical and clinical trials focused on this 
topic have already shown promising results [4–8]. 
Among the antigens used for diagnostic applications, the prostate-specific membrane antigen (PSMA) 
was demonstrated to be a useful target [9–13]. PSMA is a Type II integral membrane glycoprotein,  
which is overexpressed in prostate cancer in comparison to benign prostate tissue [11,14,15]. Next to 
expression in prostate, PSMA was found to be expressed in the neovasculature of solid tumors  
in comparison to normal vasculature [16,17]. The biological role of PSMA is not completely 
understood [10,18,19]. 
Ross et al. demonstrated a significant correlation between PSMA expression in prostate cancer  
and the Gleason score, pathological stage and biochemical recurrence [11]. Indium-111 capromab 
pendetide (ProstaScint®) is a radiolabelled antibody directed against PSMA. Correlation of scan results 
with pathological specimens suggests that ProstaScint is able to detect soft tissue metastases [20–23]. 
However, for routine use in clinical practice, the sensitivity of ProstaScint is not high enough, because 
the antibody targets the intracellular epitope of PSMA, thereby probably targeting only damaged or 
necrotic/apoptotic cells. Furthermore, the role of ProstaScint in the diagnosis of recurrent disease has 
to be elucidated [24]. 
Another antigen that can be used as an imaging target is the epithelial cell adhesion molecule (EpCAM). 
EpCAM is a transmembrane glycoprotein, which is highly expressed in rapidly proliferating tumors of 
epithelial origin [25–27]. This protein is found to be strongly expressed in several carcinomas [28–31]. 
In normal epithelium, there is a lower expression of EpCAM [32]. EpCAM mediates epithelial-specific 
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intercellular cell-adhesion. Next, it is suggested that EpCAM is involved in cell migration, signaling, 
proliferation and differentiation [33]. The expression of EpCAM is inversely related to prognosis in 
several carcinomas [33]. For prostate cancer, this relation is controversial [32,34]. 
Signal protein vascular endothelial growth factor (VEGF) and its receptors are involved in  
(tumor-related) angiogenesis [35,36]. VEGF is overexpressed in a variety of tumors, including gliomas, 
breast, renal cell and hepatocellular cancer [37]. VEGF is a potential target, as its expression has also 
been demonstrated in prostate cancer [38,39]. The expression of VEGF in normal prostate, benign 
prostate hyperplasia and prostate cancer in relation to tumor grade is inconsistent in the current  
literature [7,40–49]. As for EpCAM, the prognostic value of VEGF expression is controversial [50–53]. 
The gastrin-releasing peptide receptor (GRPR) can be a promising imaging target. GRPR is a 
glycosylated seven-transmembrane G-protein coupled receptor, which is expressed in numerous 
cancers, such as those of the lung, colon and prostate [54–59]. GRPR seems to be overexpressed in 
prostate cancer in comparison to sparse expression in normal prostate tissue [60–62]. Binding of 
GRPR stimulates the growth of prostate cancer cells in vitro and in vivo [63,64]. A significant inverse 
correlation was found between GRPR expression and an increasing Gleason score [60]. 
Currently, there is no knowledge about the expression of PSMA, EpCAM, VEGF and GRPR in 
locally recurrent prostate cancer after brachytherapy or external beam radiotherapy. Therefore, the aim 
of this pilot study was to investigate the expression of these antigens using immunohistochemistry and 
to analyze their potency for new diagnostic applications in locally recurrent prostate cancer. 
2. Results and Discussion 
2.1. Results 
In Table 1, the results of the immunohistochemical staining of different antibodies in prostate 
cancer specimens are presented.  
Table 1. Gleason sum scores, therapy characteristics and staining intensities of the antibodies 




(Dose in Gy) 
Hormonal Status 
Prior to Salvage 
Prostatectomy 
Interval between 
Radiotherapy and Salvage 
Prostatectomy (Months) 








None 45 pT2c 8 + ++ ++ +++ 
3 EBRT (70) LHRH + AA 58 pT3b 8 + - + +++ 








None 47 pT2c cnd + + - +++ 
7 EBRT (70) LHRH + AA 120 pT3a 7 +++ - + + 
8 EBRT (66) None 31 pT3b 8 + - + + 
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(Dose in Gy) 
Hormonal Status 
Prior to Salvage 
Prostatectomy 
Interval between  
Radiotherapy and Salvage 
Prostatectomy (Months) 
Stage Gleason PSMA EpCAM VEGF GRPR
9 EBRT (66) None 78 pT4 7 +++ +++ + +++ 








None 41 pT4 7 +++ +++ + ++ 
13 EBRT (70) None 49 pT3a 8 + ++ ++ ++ 




AA 88 pT3b 8 +++ ++ ++ +++ 
16 EBRT (68) None 13 pT3b 6 + ++ + ++ 
17 EBRT (70) LHRH 34 pT3b 10 +++ ++ + ++ 
cnd, could not be determined; EBRT, external beam radiotherapy; HDR, high dose rate; LDR, low dose rate; 
LHRH, luteinizing-hormone-releasing hormone agonist; AA, androgen receptor antagonist. 
Overall, staining for PSMA was seen in 100% (17/17), EpCAM in 82.3% (14/17), VEGF in 82.3% 
(14/17) and GRPR in 100% (17/17) of prostate cancer specimens. Staining for PSMA, EpCAM and 
VEGF was seen in 0% (0/17) and for GRPR in 100% (17/17) of the specimens’ stromal compartments. 
Immunohistochemical staining intensity frequency, number and percent are shown in Table 2. 























0 0 (0%) 17 (100%) 3 (17.7%) 17 (100%) 3 (17.7%) 17 (100%) 0 (0%) 0 (0%) 
1+ 7 (41.2%) - 4 (23.5%) - 7 (41.2%) - 3 (17.7%) 3 (17.7%) 
2+ 2 (11.8%) - 6 (35.3%) - 6 (35.3%) - 6 (35.3%) 8 (47.0%) 


















In 11.8% (2/17) of cases, the GRPR staining intensity of prostate cancer was higher than that of stroma. 
In 88.2% (15/17) of cases, the GRPR staining intensity of prostate cancer was equal to the staining 
intensity of stroma. Tumor distinctiveness is shown in Table 3. 
Table 3. Tumor distinctiveness. 
Tumor distinctiveness  PSMA EpCAM VEGF GRPR 
0 - 3 (17.7%) 3 (17.7%) 15 (88.2%)  
1 7 (41.2%) 4 (23.5%) 7 (41.2%) 2 (11.8%) 
2 2 (11.8%) 6 (35.3%) 6 (35.3%) - 
3 8 (47.0%) 4 (23.5%)  1 (5.8%)  - 
Tumor distinctiveness = staining intensity tumor − staining intensity stroma.  
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2.2. Staining Pattern 
PSMA staining in prostate cancer specimens was membranous and cytoplasmic (Figure 1).  
Six cases with focal uptake amidst negative cancer tissue were observed (Patient No. 2–4, 6, 8, 13) 
(Figure 1). For PSMA, there was minimal staining of prostatic intraepithelial neoplasia (PIN) and 
normal prostate epithelium. EpCAM stained cytoplasm and at the basal membrane (Figure 2). VEGF 
and GRPR staining in prostate cancer tissue was cytoplasmic and diffuse (Figures 3 and 4). Staining of 
striated muscle was observed for GRPR. 
Figure 1. PSMA staining in prostate cancer tissue. (a) Membranous and cytoplasmic 
brown staining for PSMA in prostate cancer cells, 400× magnification; (b) focal brown 
staining for PSMA in prostate cancer cells (arrows) amidst negative cancer tissue (*),  
200× magnification.  
 
Figure 2. EpCAM staining in prostate cancer tissue. Strong brown cytoplasmic staining for 
EpCAM in prostate cancer cells (arrows), 400× magnification.  
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Figure 3. VEGF staining in prostate cancer tissue. Strong brown cytoplasmic staining for 
VEGF in prostate cancer cells, 200× magnification.  
 
Figure 4. GRPR staining in prostate cancer tissue. (a) Strong brown cytoplasmic staining 
for GRPR in prostate cancer cells and weak background staining of prostate stromal cells; 
(b) equal staining intensity of prostate cancer and stroma, 200× magnification.  
 
2.3. Discussion 
This study has shown that PSMA, EpCAM, VEGF and GRPR are expressed in locally recurrent 
prostate cancer after brachytherapy and external beam radiotherapy. Staining for PSMA and GRPR 
was observed in all prostate cancer specimens (17/17), while EpCAM and VEGF staining was 
observed in 82.3% (14/17) of cases (Tables 1 and 2). Staining for PSMA, EpCAM and VEGF was 
absent (0/17) in specimens’ stromal compartments, while GRPR staining in stroma was observed in 
100% (17/17) of cases. In 88.2% (15/17) of cases, the GRPR staining intensity of prostate cancer was 
equal to the staining intensity of stroma. Staining of striated muscle was observed for GRPR, which is 
in agreement with the findings of other groups [60–62].  
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The high expression of PSMA, EpCAM, VEGF and GRPR in locally recurrent prostate cancer after 
ionizing therapy could have several reasons, which will be postulated next. First, high expression of 
either antigen is correlated with a tendency for recurrence. This holds true for PSMA, as its expression 
in primary prostate cancer is positively correlated with factors, like a high Gleason grade, a higher 
tumor stage and, most important in this case, biochemical recurrence [11,18]. The same goes for 
EpCAM, as a recent study by Benko et al. showed that higher EpCAM expression correlated with a 
higher Gleason score and a shorter disease-free survival [34]. However, other research groups found 
conflicting results [26,30,65]. Expression of VEGF in prostate cancer positively correlated with high a 
Gleason score, lymph node metastases and the progression of disease [66]. Although there is no 
information about GRPR expression and recurrence, the process might be comparable. 
Second is the upregulation of antigens due to radiotherapy. It has been demonstrated that VEGF  
is upregulated after radiotherapy for rectal cancer [67]. For EpCAM, PSMA and GRPR, this is 
currently unknown. Third, recurrent cancer could have the tendency for upregulation of certain antigens. 
In ovarian cancer, EpCAM upregulation was seen in recurrent cancer when compared to primary 
cancer in matched samples [68], while VEGF levels were significantly higher in recurrent acute 
lymphoblastic leukemia compared with newly diagnosed cases [69]. For all the postulations, we  
have no direct evidence, as we did not have prostate cancer biopsy samples before and after radiation 
therapy that could have been compared to the salvage prostatectomy samples.  
The absence of non-specific background staining of normal tissue or prostate stroma for the anti-PSMA, 
EpCAM and VEGF antibodies proves the specificity for cancer tissue. Background staining for GRPR 
was evident. Although different protocols were used and different blocking agents were tested, 
staining of non-cancer tissue remained. Staining of normal prostate and muscle with the anti-GRPR 
antibody has been described in the literature by other authors [60–62], and at first glance, this might 
pose a problem for the future use of GRPR as a target for new therapeutic or diagnostic modalities. 
However, pre-clinical and clinical studies have shown very low uptake of GRPR-targeted  
bombesin-like radiopharmaceuticals in muscle with high tumor-to-muscle ratios [70].  
The current study has several limitations. First, we did not have matched samples of prostate  
cancer tissue. In an ideal situation, we would have compared prostate biopsy samples at initial 
diagnosis before radiation therapy, the biopsy samples in which local recurrence was confirmed after 
radiation therapy and the salvage prostatectomy samples; Second, staining intensity was assessed 
qualitatively on a scale from zero to three. Although strong staining suggests a higher antigen density than 
weak staining does, it is impossible to make a comparison between the different antibodies used in this 
study, as different protocols were used and as there is most likely different antigen sensitivity for each 
antibody. A quantification of antigen-densities has to be performed to be able to make a comparison 
between antigens; Third, due to the low number of patients (n = 17), the power of the statistics would be 
too weak, and therefore, we were unable to correlate staining intensity with clinicopathological parameters.  
Finally, we did not have the follow-up data to compare antigen expression with outcome. 
There is not much knowledge about the expression of antigens in recurrent prostate cancer. Locally 
recurrent prostate cancer is, to our knowledge, an unexplored field. Therefore, this is the first study to 
show the data about the expression of PSMA, VEGF, EpCAM and GRPR in locally recurrent prostate 
cancer after ionizing therapy.  
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Antigen-based targeted imaging of the prostate could be useful in several scenarios: if salvage local 
therapy was planned without a biopsy or with repeated negative biopsies, but with a strong suspicion 
of local recurrence. Other applications for these imaging strategies would be to rule out 
micrometastatic disease prior to local salvage therapy or the application of salvage focal therapy only 
to areas of uptake on imaging in order to minimize side-effects in irradiated tissue. The unique 
overexpression on prostate cancer cells makes PSMA the most attractive target for the delivery of 
imaging agents [10]. Several clinical studies with PSMA as the target have been reported with 
encouraging results [71,72]. Bombesin-like radiopharmaceuticals, which are natural ligands of GRPR, 
can be relatively easy synthesized in large quantities and have shown promising results in several 
clinical studies [70]. However, due to its background staining, more careful selection of the protocol 
may be required for optimal targeting. Only a few studies consider VEGF and EpCAM-based diagnostics 
for targeted cancer imaging [73–75], but based on the results reported in this study, both antigens can be 
used for the detection of locally recurrent prostate cancer. 
3. Experimental Section 
3.1. Materials 
Patients in our retrospective study were diagnosed with locally recurrent prostate cancer based on 
PSA relapse and transrectal ultrasound-guided prostate biopsies. Prostate cancer specimens were 
collected of 17 patients who underwent salvage prostatectomy (The Netherlands Cancer Institute, 
Antoni van Leeuwenhoek Hospital Amsterdam (NKI/AVL)), because of locally recurrent prostate 
cancer after brachytherapy (4 patients) or external beam radiotherapy (13 patients). All tissue 
specimens were anonymous and encoded with a unique code. According to Dutch law, no further 
Institutional Review Board approval was required (http://www.federa.org). Pretreatment biopsies were 
not available. 
3.2. Immunohistochemistry 
Formalin-fixed, paraffin-embedded blocks of prostate tissue were cut into 4-mm-thick sections and 
mounted on Starfrost microscope slides. Hematoxylin and eosin stained sections were graded by an 
experienced pathologist (Stefano Rosati), based on the criteria of the Gleason grading system. 
Remaining sections were processed for immunohistochemistry. 
3.2.1. PSMA 
After deparaffinization, antigen retrieval was performed by heating microwave (700 W) for  
20 min in a 10 mM citrate buffer at pH 6.0, with a cool down period of 20 min afterwards.  
Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in phosphate-buffered saline (PBS) 
for 20 min. Slides were than incubated with the primary anti-human-PSMA mouse monoclonal antibody, 
YPSMA-1 (Abcam, Cambridge, UK), diluted at 1:400 in 1% bovine serum albumin/phosphate-buffered 
saline (1% BSA/PBS) for 1 h at room temperature. The secondary step consisted of incubation with 
rabbit anti-mouse antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, 
Denmark), diluted at 1:100 in 1% BSA/PBS with 1% AB serum. For the tertiary step, goat anti-rabbit 
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antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark) was used, 
diluted at 1:100 in 1% BSA/PBS with 1% AB serum. Both the secondary and tertiary step required 
incubation for 30 min at room temperature. Next, the slides were immersed for 10 min in a solution of 
0.05% 3,3'-diaminobenzidine (Sigma-Aldrich, St. Louis, MO, USA) and 0.03% hydrogen peroxide in 
PBS for the visualization of the signal as brown staining. After washing with demineralized water, the 
slides were slightly counterstained with hematoxylin, dehydrated and mounted with Eukitt mounting 
medium (Sigma-Aldrich, Steinheim, Germany). 
3.2.2. GRPR 
After deparaffinization, antigen retrieval was performed by heating microwave (700 W) for 20 min 
in 0.1 M Tris/HCl buffer at pH 9.0, with a cool down period of 20 min afterwards. Endogenous 
peroxidase was blocked with 0.3% hydrogen peroxide in Tris-buffered saline (TBS) for 20 min.  
Slides were then incubated with a normal goat serum diluted at 1:10 in TBS for 30 min at  
room temperature. Afterwards, the slides were incubated with the primary anti-human-GRPR rabbit 
polyclonal antibody, ab39963 (Abcam, Cambridge, UK), diluted at 1:250 in 1% BSA/TBS overnight at 
4 °C. Only a secondary step with goat anti-rabbit antibody conjugated to polymer-horseradish 
peroxidase (DAKO, Glostrup, Denmark) was applied, diluted at 1:100 in 1% BSA/TBS with 1% AB 
serum for 60 min at room temperature. Next, the slides were immersed for 10 min in a solution of 
0.05% 3,3'-diaminobenzidine (Sigma-Aldrich, Steinheim, Germany) and 0.03% hydrogen peroxide in 
PBS for the visualization of the signal as brown staining. After washing with demineralized water, the 
slides were slightly counterstained with hematoxylin, dehydrated and mounted with Eukitt mounting 
medium (Sigma-Aldrich, Steinheim, Germany). 
3.2.3. EpCAM 
After deparaffinization, antigen retrieval was performed by incubation with 0.1% protease for 30 min 
at room temperature. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide in PBS  
for 20 min. Slides were than incubated with the primary mouse monoclonal anti-EpCAM antibody 
(Clone VU-1D9, Leica Biosystems, Newcastle, UK) diluted at 1:100 in 1% BSA/PBS for 1 h at  
room temperature. The secondary step consisted of incubation with rabbit anti-mouse antibody 
conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, Denmark), diluted at 1:100 in 1% 
BSA/PBS with 1% AB serum. For the tertiary step, goat anti-rabbit antibody conjugated to  
polymer-horseradish peroxidase (DAKO, Glostrup, Denmark) was used, diluted at 1:100 in 1% 
BSA/PBS with 1% AB serum. Both the secondary and tertiary step required incubation for 30 min  
at room temperature. Next, the slides were immersed for 10 min in a solution of 0.05%  
3,3'-diaminobenzidine (Sigma-Aldrich, Steinheim, Germany) and 0.03% hydrogen peroxide in PBS 
for visualization of the signal as brown staining. After washing with demineralized water, the slides 
were slightly counterstained with hematoxylin, dehydrated and mounted with Eukitt mounting medium 
(Sigma-Aldrich, Steinheim, Germany). 




After deparaffinization, microwave antigen retrieval (700 W) was performed for 20 min in  
10 mM Tris/1 mM EDTA buffer at pH 9.0, with a cool down period of 20 min afterwards. Endogenous 
peroxidase was blocked with 0.3% hydrogen peroxide in PBS for 20 min. Slides were incubated with a 
normal goat serum diluted at 1:10 in PBS for 30 min at room temperature. The primary step consisted 
of incubation with rabbit anti-human antibody VEGF A-20 sc-152, (Santa Cruz Biotechnology,  
Santa Cruz, CA, USA) diluted at 1:200 in 1% BSA/PBS for 1 h at room temperature. Only a secondary 
step with goat anti-rabbit antibody conjugated to polymer-horseradish peroxidase (DAKO, Glostrup, 
Denmark) was applied, diluted at 1:100 in 1% BSA/TBS with 1% AB serum for 30 min at room 
temperature. Next, the slides were immersed for 10 min in a solution of 0.05% 3,3'-diaminobenzidine 
(Sigma-Aldrich, Steinheim, Germany) and 0.03% hydrogen peroxide in PBS for the visualization of 
the signal as brown staining. After washing with demineralized water, the slides were slightly 
counterstained with hematoxylin, dehydrated and mounted with Eukitt mounting medium  
(Sigma-Aldrich, Steinheim, Germany). 
3.3. Assessment of Staining Patterns 
The assessment of staining patterns was performed as described before [8]. For each antigen, a 
pathologist (Stefano Rosati) blinded to clinical and pathological data, scored the staining intensity  
(0 = no staining; 1+ = weak staining; 2+ = moderate staining; 3+ = strong staining) of tumor areas for 
all the specimens. Specimens in which one or more tumor areas with different staining intensities were 
present were scored for the most prevalent intensity. Specimens with focal uptake amidst negative 
cancer tissue scored 1+. Furthermore, different patterns of immunoreactivity were observed and 
documented. To evaluate background staining, all specimens were evaluated in a field that contained 
both prostate cancer and stroma. Tumor distinctiveness was assessed for each antigen by subtracting 
the staining intensity of stroma from the staining intensity of prostate cancer.  
4. Conclusions  
The current study is the first to present data on the expression of PSMA, EpCAM, VEGF and 
GRPR in locally recurrent prostate cancer after brachytherapy or external beam radiotherapy. Based on 
the absence of stromal staining, PSMA, EpCAM and VEGF show high tumor distinctiveness. GRPR 
has a very low tumor distinctiveness. Therefore, PSMA, EpCAM and VEGF can be used as targets for 
the bioimaging of recurrent prostate cancer after EBRT to exclude metastatic disease and/or to plan 
local salvage therapy.  
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